Loading…
← CockpitCompetitor Analysis › OVID Ovid Therapeutics Inc.Open in the cockpit ↗

Ovid Therapeutics Inc.OVIDCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 38
Mkt cap
$427M
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$6.36M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-78.9 pp
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
117 days
15 Mar 2027
Close · USD$2.26
1D+1.8%
1W-18.7%
1M-4.2%
3M-17.5%
6M-5.4%
YTD+38.6%
1Y+73.8%
ATR %9.8%
Beta1.44
52w lowhigh27.2% off high

What Ovid Therapeutics does

Employees: 23

Ovid Therapeutics at a glance

Size Ovid Therapeutics (OVID) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $427M, the 2792nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.26 on 18 Nov 2026.

Performance Over six months the shares fell 5.4%, against -25.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue fell 78.0% over the last twelve months (peer median +7.2%); the operating margin is -4,700.3% (peer median 1.5%).

Valuation It trades at 208.3× enterprise value to sales against a peer median of 2.9× (most expensive of 19).

Capital Return on invested capital runs 78.9 points below its cost of capital (6.5% WACC).

Next results Next results expected around 15 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026OVID 93Peer median 77
Six months, rebased to 100: Ovid Therapeutics against the median of its 20 peers (local-currency closes).

Ovid Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.45M$7.25M$566,000$391,695$1.50M
Revenue growth—+1,181%+45%-74%—
Gross profit$1.34M$6.95M-$34,000-$1.20M$121,142
EBITDA-$68.1M-$42.1M-$61.3M-$57.7M-$54.2M
Net income-$43.1M-$17.4M-$26.4M-$52.3M-$54.2M
Free cash flow-$57.8M-$38.3M-$56.0M-$45.8M-$56.5M
Capital expenditure$0$0$161,000$137,455$1.42M
Total debt$12.4M$13.4M$14.8M$46.0M$16.5M

Quarterly statements and history in the cockpit →

Ovid Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%ZOTA6006130484100029234114601089001060PHATTVGN6031396881176050776881360027280005180007880029000024627871RZLTOVID6-month return →1-month return →
Up and to the right = strong over both horizons. Ovid Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×100×200×ZOTA6006130484100005187871OVIDRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ovid Therapeutics is the large dot.

Ovid Therapeutics competitors and peer comparison

How Ovid Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ovid Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureOVIDPeer medianRank in peer set
1-month return-4.2%-13.0%3rd highest of 21
6-month return-5.4%-25.4%6th highest of 21
Distance from 52-week high-27.2%-49.4%3rd highest of 21
Revenue growth (TTM)-78.0%+7.2%lowest of 19
Operating margin-4,700.3%1.5%lowest of 19
EV / Sales208.3×2.9×most expensive of 19
ROIC minus cost of capital-78.9 pp-5.9 pp2nd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%3.4×-0.2%+14.5%
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%1.1×n/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%2.9×n/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%10.6×n/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%2.1×-5.6%-5.6%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%4.2×n/an/a
Cachet Pharmaceutical 002462.SZChina$441M-25%-14%0%0.2×-9.9%-3.4%
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a

Questions

Which companies are Ovid Therapeutics's closest peers?
The cockpit's peer set: Zota Health Care (ZOTA.NS), Shanghai Shenqi Pharmaceutical Investment Management (600613.SS), Hyundai Bioscience (048410.KS), Zhuhai Rundu Pharmaceutical (002923.SZ), Synmosa Biopharma (4114.TWO), Beijing Foyou Pharma (601089.SS), JW Pharmaceutical (001060.KS), Phathom Pharmaceuticals (PHAT).
Is Ovid Therapeutics expensive compared with its peers?
On ev / sales it trades at 208.3× against a peer median of 2.9×, most expensive of 19 in its peer set.
How has Ovid Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -5.4% against -25.4% for the median peer; over one year +73.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.